Rodabe N. Amaria

Rodabe N. Amaria is a Professor in the Department of Melanoma Medical Oncology at The University of Texas MD Anderson Cancer Center. She holds an M.D. and specializes in oncology, dermatology, and cancer immunotherapy. Her research focuses on neoadjuvant immunotherapy for resectable melanoma, immune checkpoint inhibitors (anti-PD-1, anti-LAG-3), and cellular therapy, including engineered tumor-infiltrating lymphocytes. Her recent work includes first-in-human trials of SOCS1-inactivated TIL therapy, intratumoral CD40 agonism with pembrolizumab, and biomarker analyses of long-term survival. She has led pivotal trials such as the Morpheus-Melanoma study and has published extensively in Nature Medicine, Journal of Clinical Oncology, and Cancer Discovery.